Yangzhou, China --- Shanghai Intbot Robotic Co., Ltd., a joint venture of Shanghai MicroPort MedBot (Group) Co., Ltd. (“MicroPort^® MedBot^®”) and Biobot Surgical Pte. Ltd. of Singapore, introduced Mona Lisa Robotic Prostate Puncture Positioning System (“Mona Lisa”), successfully held the kick-off ceremony for clinical trial in Northern Jiangsu People's Hospital on January 13^th, 2022. Dousheng Bai, Director of Medical Administration Department, Xuefei Ding, Director of Urology Department, Jia Tang, Director of Publicity Department, Jing Ye, Director of Imaging Department, Chongxu Han, Director of Laboratory Department, Xiaofang Ye, head nurse of Endoscopy Department, Yanyan He, Director of Ethics Office and Mr. Hongjun He, General Manager of Intbot Robotic attended the ceremony. Earlier, the clinical trial of Mona Lisa was launched in Nanjing Drum Tower Hospital and the First Affiliated Hospital of Xi 'an Jiaotong University, where multiple surgeries had been completed and it is also the first batch clinical trial surgery of robot-assisted prostate puncture biopsy in China.

 Compared with traditional manual puncture, Mona Lisa can make out a plan through the intelligent software, developed an image fusion module for combined 3D ultrasound and MRI visualization in image-guided navigation, automatically plan the puncture path, real-time guidance and assistance to doctors to take biopsy samples more safely, accurately, intelligently and efficiently. It can reduce the risk of urethra or rectum bleeding infection, reduce the quantity of wounds and relieve the pain of patients.

 Xuefei Ding, director of the Urology Department of Northern Jiangsu People's Hospita, said: "Mona Lisa robot is expected to significantly improve the detection rate of prostate cancer and avoid damaging the rectum and urethra of patients. It is of great clinical significance. It can not only assist doctors to achieve precision medicine, that is, minimize iatrogenic damage, but also minimize medical costs and maximize patient benefits.”

 Mr. Yu Liu, Chief Commercial Officer of MicroPort^® MedBot^®, said, "The kick-off meeting marked a phased progress in the multicenter clinical trial of Mona Lisa robotic prostate puncture positioning system. We look forward to completing the clinical trial with the highest quality, serving the vast number of patients with the generalized high-end surgical treatment solutions, and ‘Make Surgery Easier, Safer and Less Invasive’".